Xixi Zhao

Xixi Zhao

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2024 in Clinical and Translational Medicine
Verified
Journal Article
Open access
XSXiaobo Shi
Xiaobo Shi
XZXiaozhi Zhang
Xiaozhi Zhang
XHXinran Huang
Xinran Huang
RZRuijuan Zhang
Ruijuan Zhang
SPShupei Pan
Shupei Pan
XZXixi Zhao
Xixi Zhao
Background: Radiotherapy is a primary therapeutic modality for esophageal squamous cell carcinoma (ESCC), but its effectiveness is still restricted due to the resistance of cancer cells to radiation. Long non‐coding RNAs (lncRNAs) and N6‐methyladenosine (m6A) have been shown to play significant roles in tumour radioresistance. However, the precise manifestation and role of m6A‐modified lncRNAs in ESCC radioresistance remain unclear.Methods: Bioinformatics analysis was conducted to identify m6A‐modified lncRNAs implicated in the radioresistance of ESCC. A series of functional experiments were performed to investigate the function of LNCAROD in ESCC. Methylated RNA immunoprecipitation, chromatin isolation by RNA purification‐mass spectrometry, RNA immunoprecipitation, and co‐immunoprecipitation experiments were performed to explore the mechanism of m6A‐mediated upregulation of LNCAROD expression and the downstream mechanism enhancing the radioresistance of ESCC. The efficacy of LNCAROD in vivo was assessed using murine xenograft models.Results: Herein, we identified LNCAROD as a novel METTL3‐mediated lncRNA that enhanced radioresistance in ESCC cells and was post‐transcriptionally stabilised by YTHDC1. Moreover, we confirmed that LNCAROD prevented ubiquitin‐proteasome degradation of PARP1 protein by facilitating PARP1‐NPM1 interaction, thereby contributing to homologous recombination‐mediated DNA double‐strand breaks repair and enhancing the radiation resistance of ESCC cells. Silencing LNCAROD in a nude mouse model of ESCC in vivo resulted in slower tumour growth and increased radiosensitivity.Conclusion: Our findings enhance the understanding of m6A‐modified lncRNA‐driven machinery in ESCC radioresistance and underscore the significance of LNCAROD in this context, thereby contributing to the development of a potential therapeutic target for ESCC patients.

25 July 2023 in Cancer Science
Verified
Journal Article
Open access
MLMengjie Liu
Mengjie Liu
CLChaofan Li
Chaofan Li
JQJingkun Qu
Jingkun Qu
SSShiyu Sun
Shiyu Sun
ZZZitong Zhao
Zitong Zhao
XZXixi Zhao
Xixi Zhao
Triple‐negative breast cancer (TNBC) is a special pathological type of breast cancer (BC) with poor prognosis. Obesity is shown to be involved in TNBC tumor progression. The interaction between obesity and BC has generated great attention in recent years, however, the mechanism is still unclear. Here, we showed that leptin secreted by adipocytes upregulated PD‐L1 expression in TNBC through the p‐STAT3 signaling pathway and that baicalein inhibited PD‐L1 expression in tumor microenvironment by suppressing leptin transcription of adipocytes. Collectively, our findings suggest that leptin may be the key factor participating in obesity‐related tumor progression and that baicalein can break through the dilemma to boost the anti‐tumor immune response.

24 April 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Jingkun QuJingkun Qu
Jingkun Qu
CLChaofan Li
Chaofan Li
MLMengjie Liu
Mengjie Liu
YWYusheng Wang
Yusheng Wang
ZFZeyao Feng
Zeyao Feng
XZXixi Zhao
Xixi Zhao
Background: Occult breast cancer (OBC) is an uncommon malignant tumor and the prognosis and treatment of OBC remain controversial. Currently, there exists no accurate prognostic clinical model for OBC, and the treatment outcomes of chemotherapy and surgery in its different molecular subtypes are still unknown. Methods: The SEER database provided the data used for this study’s analysis (2010–2019). To identify the prognostic variables for patients with ODC, we conducted Cox regression analysis and constructed prognostic models using six machine learning algorithms to predict overall survival (OS) of OBC patients. A series of validation methods, including calibration curve and area under the curve (AUC value) of receiver operating characteristic curve (ROC) were employed to validate the accuracy and reliability of the logistic regression (LR) models. The effectiveness of clinical application of the predictive models was validated using decision curve analysis (DCA). We also investigated the role of chemotherapy and surgery in OBC patients with different molecular subtypes, with the help of K-M survival analysis as well as propensity score matching, and these results were further validated by subgroup Cox analysis. Results: The LR models performed best, with high precision and applicability, and they were proved to predict the OS of OBC patients in the most accurate manner (test set: 1-year AUC = 0.851, 3-year AUC = 0.790 and 5-year survival AUC = 0.824). Interestingly, we found that the N1 and N2 stage OBC patients had more favorable prognosis than N0 stage patients, but the N3 stage was similar to the N0 stage (OS: N0 vs. N1, HR = 0.6602, 95%CI 0.4568–0.9542, p < 0.05; N0 vs. N2, HR = 0.4716, 95%CI 0.2351–0.9464, p < 0.05; N0 vs. N3, HR = 0.96, 95%CI 0.6176–1.5844, p = 0.96). Patients aged >80 and distant metastases were also independent prognostic factors for OBC. In terms of treatment, our multivariate Cox regression analysis discovered that surgery and radiotherapy were both independent protective variables for OBC patients, but chemotherapy was not. We also found that chemotherapy significantly improved both OS and breast cancer-specific survival (BCSS) only in the HR−/HER2+ molecular subtype (OS: HR = 0.15, 95%CI 0.037–0.57, p < 0.01; BCSS: HR = 0.027, 95%CI 0.027–0.81, p < 0.05). However, surgery could help only the HR−/HER2+ and HR+/HER2− subtypes improve prognosis. Conclusions: We analyzed the clinical features and prognostic factors of OBC patients; meanwhile, machine learning prognostic models with high precision and applicability were constructed to predict their overall survival. The treatment results in different molecular subtypes suggested that primary surgery might improve the survival of HR+/HER2− and HR−/HER2+ subtypes, however, only the HR−/HER2+ subtype could benefit from chemotherapy. The necessity of surgery and chemotherapy needs to be carefully considered for OBC patients with other subtypes.

24 September 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
YWYuchen Wang
Yuchen Wang
RZRuijuan Zhang
Ruijuan Zhang
XHXinran Huang
Xinran Huang
XHXinyu He
Xinyu He
SGShangyi Geng
Shangyi Geng
XZXixi Zhao
Xixi Zhao

1 September 2021 in Clinica Chimica Acta
Verified
Journal Article
Open access
YCYinxi Chen
Yinxi Chen
XZXixi Zhao
Xixi Zhao
LWLi Wang
Li Wang
FWFei Wu
Fei Wu
XZXin Zhang
Xin Zhang
SZShuqun Zhang
Shuqun Zhang
ESR1 mutation is an important mechanism of drug resistance and recurrence in hormone receptor-positive breast cancer patients during AI treatment. Patient could still benefit from treatment with fulvestrant after ESR1 mutated. At present, there is still no suitable method to detect ESR1 mutation in plasma as clinical promotion method. We aim to improve from ARMS-PCR to get a method with higher sensitivity but no additional cost is incurred. We designed new primers for ESR1. Then positive and negative standard sample was used for sensitivity and specificity tests. Lastly, we collected patient peripheral blood sample and analyzed the performance of Super-ARMS in plasma ctDNA samples. A total of 207 patients were enrolled in this study, including 142 prime breast cancer (PBC) patients and 65 metastasis breast cancer(MBC) patients. The mutation rate was as high as 27.9%(12/43) in MBC patients with AI treatment. But only 2.97%(3/101) in PBC patients with AI and 0% in both MBC or PBC patient without AI. There was no significant difference in Super-ARMS results compared with DDPCR method. Super-ARMS is a method that has sensitivity close to DDPCR and has the convenience and low price of ARMS-PCR for plasma ctDNA ESR1 mutation detection. It has obvious advantages compared with other method such NGS and DDPCR as clinical promotion method.

16 October 2024 in Oncology and Translational Medicine
Verified
Journal Article
Open access
XZXixi Zhao
Xixi Zhao
XHXinyu He
Xinyu He
XLXiaoxiao Liu
Xiaoxiao Liu
SGShangyi Geng
Shangyi Geng
YWYuchen Wang
Yuchen Wang
HMHongbing Ma
Hongbing Ma
Background: Both eczema and tumor are associated with immune disorders. Although several investigations have observed the relationship between eczema and certain cancers, evidence for causality is lacking. Methods: We conducted a two-sample Mendelian randomization (MR) study to examine and explore the genetic association between eczema and pan-cancers. Upon satisfying the three core assumptions of MR, we analyzed the causality between eczema and 15 site-specific cancers utilizing an inverse variance weighted method. We verified the results through a series of sensitivity and reverse direction analyses. The exposure and outcome datasets were substituted from the FinnGen and genome-wide association studies catalog databases. A meta-analysis on primary and validation analyses was performed to combine the estimates of MR study. Results: Based on the MR analysis results, eczema was associated with an increased risk of lung cancer (odds ratio [OR] = 1.0427, 95% confidence interval [CI] = 1.0082–1.0783, P = 0.0148) and brain cancer (OR = 1.0285, 95% CI = 1.0120–1.0452, P = 0.0007) and decreased risk of colorectal cancer (OR = 0.9324, 95% CI = 0.8774–0.9909, P = 0.0242) and malignant neoplasm of the kidney (OR = 0.9323, 95% CI = 0.8834–0.9839, P = 0.0108). The sensitivity analysis indicated that the results were stable and reliable, and the reverse MR analyses demonstrated no causation between the cancers of interest and eczema. Conclusions: Our results identified eczema as a genetic risk factor for lung and brain cancer and a protective factor for colorectal cancer and malignant neoplasm of the kidney. No connection was observed between eczema and other cancers. Further evidence from epidemiological and mechanistic studies is needed to elucidate these findings in detail.